We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

GAP:NYSEGap, Inc. (The) Analysis

Data as of 2026-09-02 - not real-time

$22.23

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

The Gap, Inc. trades at $22.23, with its moving averages tangled rather than clearly stacked — a neutral trend structure. It has gained 13.1% over the past 30 days. Momentum indicators put RSI at 59.6 (neutral) with MACD reading bullish. Recent trading has carved out support near $19.52 and resistance around $25.80.
The shares look undervalued at 6.8 times earnings, though no sector average was available for comparison. Sell-side targets cluster 20.1% above the current quote. Revenue is contracting at 2.0% on a 8.1% profit margin. The 3.18% dividend yield looks covered by current payout levels.
Risk scores 7 out of 10, which is elevated for this asset class. With 30-day volatility of 51.4%, a beta of 1.19 and a maximum drawdown of 37.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
Timeframes disagree: the short-term read is hold while the long-term read is buy, conviction 5 out of 10.

Top Market Events

Gap Inc. NYSE:GAP just delivered one of its more contradictory quarters in years on August 27. Total sales fell 2%, yet...Options traders are targeting Gap GAP ahead of tomorrow's earnings report, while the stock is staging a pre-earnings...Gap stock gets a boost as Trump's tariff refunds come home to roost.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 4/10

Key Factors

  • Trading below the 200-day average of 23.94
  • MACD momentum is positive
  • 30-day price change of +13.1%

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Trading below the 200-day average of 23.94
  • Analyst targets imply +20.1% versus the current price
  • 30-day volatility of 51.4%

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • Analyst targets imply +20.1% versus the current price
  • Revenue contracting at -2.0%
  • P/E ratio of 6.8

Key Metrics & Analysis

Financial Health

Revenue Growth-2.00%
Profit Margin8.14%
P/E Ratio6.8
ROE33.78%
ROA4.78%
Debt/Equity144.77
P/B Ratio2.0
Op. Cash Flow$1.5B
Free Cash Flow$246.4M

Technical Analysis

TrendNeutral
RSI59.6
Support$19.52
Resistance$25.80
MA 20$20.85
MA 50$20.19
MA 200$23.94
MACDBullish
VolumeIncreasing
Fear & Greed Index92.86

Valuation

Target Price$26.69
Upside/Downside20.08%
GradeUndervalued
TypeValue
Dividend Yield3.18%

Risk Assessment

Beta1.19
Volatility51.43%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.